AP NEWS
Click to copy
Press release content from BusinessWire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

UroGen Pharma to Present at November 2018 Investor Conferences

November 6, 2018

RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)--Nov 6, 2018--UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in November 2018:

Stifel 2018 Healthcare Conference Tuesday, November 139:30AM Eastern TimeNew York, NY Jefferies 2018 London Healthcare Conference Thursday, November 159:20AM Greenwich Mean TimeLondon, UK

A live audio webcast of each event will be available on the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.

About UroGen Pharma Ltd.

UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead product candidates, UGN-101 and UGN-102, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. UroGen is headquartered New York, NY with offices in Ra’anana, Israel and Los Angeles, CA.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181106005059/en/

CONTACT: UroGen Pharma Ltd.

Kate Bechtold, 914-552-0456

Director, Corporate Communications & Investor Relations

Kate.Bechtold@urogen.com

KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA NEW YORK MIDDLE EAST ISRAEL

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: UroGen Pharma Ltd.

Copyright Business Wire 2018.

PUB: 11/06/2018 08:00 AM/DISC: 11/06/2018 08:01 AM

http://www.businesswire.com/news/home/20181106005059/en

All contents © copyright 2019 The Associated Press. All rights reserved.